Targeting toll-like receptors for drug development: a summary of commercial approaches

被引：51

作者：

Gearing, Andrew J. H.

机构：

[1] Monash Med Ctr, Biocomm Squared, Melbourne, Vic 3168, Australia

[2] Monash Univ, Monash Inst Med Res, Clayton, Vic 3168, Australia

来源：

IMMUNOLOGY AND CELL BIOLOGY | 2007年 / 85卷 / 06期

关键词：

commercial approaches; drug targets; toll-like receptors;

D O I：

10.1038/sj.icb.7100102

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Toll-like receptors (TLRs) play a fundamental role in recognizing infectious and noxious agents as well as products of tissue damage. They are capable of initiating both protective and damaging inflammatory and immune responses. Several biotechnology and pharmaceutical companies have programmes to develop new drugs that are either: agonists of TLRs to enhance immune responses against tumours and infectious agents, or to correct allergic responses; or antagonists designed to reduce inflammation due to infection or autoimmune disease. This article reviews the commercial approaches being undertaken to develop new TLR drugs.

引用

收藏

页码：490 / 494

页数：5

相关论文

共 61 条

[1] Pathogen recognition and innate immunity [J].

Akira, S ;

Uematsu, S ;

Takeuchi, O .

CELL, 2006, 124 (04) :783-801

[2] A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling [J].

Bowie, A ;

Kiss-Toth, E ;

Symons, JA ;

Smith, GL ;

Dower, SK ;

O'Neill, LAJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (18) :10162-10167

[3] The role of Toll-like receptor signalling in the pathogenesis of arthritis [J].

Brentano, F ;

Kyburz, D ;

Schorr, O ;

Gay, R ;

Gay, S .

CELLULAR IMMUNOLOGY, 2005, 233 (02) :90-96

[4] Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis [J].

Casale, Thomas B. ;

Kessler, Jean ;

Romero, Francisco A. .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2006, 97 (04) :454-456

[5] Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus [J].

Christensen, Sean R. ;

Shupe, Jonathan ;

Nickerson, Kevin ;

Kashgarian, Michael ;

Flavell, Richard A. ;

Shlomchik, Mark J. .

IMMUNITY, 2006, 25 (03) :417-428

[6] Structural complementarity of Toll/interleukin-1 receptor domains in toll-like receptors and the adaptors Mal and MyD88 [J].

Dunne, A ;

Ejdebäck, M ;

Ludidi, PL ;

O'Neill, LAJ ;

Gay, NJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :41443-41451

[7] Expression of toll-like receptors in human atherosclerotic lesions - A possible pathway for plaque activation [J].

Edfeldt, K ;

Swedenborg, J ;

Hansson, GK ;

Yan, ZQ .

CIRCULATION, 2002, 105 (10) :1158-1161

[8] Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction [J].

Favre, Julie ;

Musette, Philippe ;

Douin-Echinard, Victorine ;

Laude, Karine ;

Henry, Jean-Paul ;

Arnal, Jean-Francois ;

Thuillez, Christian ;

Richard, Vincent .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (05) :1064-1071

[9] Viral and nonviral uses of imiquimod: A review [J].

Gupta, AK ;

Cherman, AM ;

Tyring, SK .

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2004, 8 (05) :338-352

[10] The poxvirus protein A52R targets toll-like receptor signaling complexes to suppress host defense [J].

Harte, MT ;

Haga, IR ;

Maloney, G ;

Gray, P ;

Reading, PC ;

Bartlett, NW ;

Smith, GL ;

Bowie, A ;

O'Neill, LAJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (03) :343-351

← 1 2 3 4 5 6 7 →